Results 141 to 150 of about 24,289 (229)

<i>In vitro</i> activities of aztreonam/nacubactam and cefepime/nacubactam against a global collection of molecularly characterized Enterobacterales isolates carrying carbapenemases: a global antimicrobial resistance surveillance study from 2021 to 2023. [PDF]

JAC Antimicrob Resist
Estabrook M, Suzuki E, Shimizu A, Okade H.   +3 more
europepmc   +1 more source

Carbapenem-Resistant Enterobacterales (CRE) in Europe: Surveillance Challenges, Emerging Threats and Public Health Preparedness. [PDF]

Antibiotics (Basel)
Kuszewska K, Klesiewicz K, Leśniak P, Chmielarczyk A.   +3 more
europepmc   +1 more source

<i>In vitro</i> susceptibility testing of aztreonam-avibactam against predominantly NDM-producing <i>Enterobacterales</i> in Peru. [PDF]

Microbiol Spectr
Garcia C, Reyes Y, Astocondor L, Caytuiro L, Riveros M, Amaro C, Andrade S, Hernández L, Sandoval R, Peréz-Lazo G, Cucho C, Melo M, Sabogal I, Lino L, Cuaresma E, Olivares A, Lachira A, Michilot K, Ramos J, Diaz R, Briones A, Burgos S, Cuicapuza D, Tsukayama P, Krapp F.   +24 more
europepmc   +1 more source

In Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacilli. [PDF]

Antibiotics (Basel)
Karlowsky JA, Wise MG, Shi Q, Zhang W, Le M, Li J.   +5 more
europepmc   +1 more source

Real-world use of eravacycline for the treatment of mono- and polymicrobial infections involving Enterobacterales

Bacterial species in the Enterobacterales order are commonly encountered causative organisms in hospital-acquired infections. Furthermore, the incidence of carbapenem-resistant Enterobacterales (CRE) is a growing threat worldwide. Eravacycline (ERV) is a
Andrade, Justin, King, Madeline A, Molina, Kyle C, Claeys, Kimberly C, Jones, Bruce M, Schrack, Melanie Rae, Van Helden, Sean R, DeKerlegand, Alaina, Tart, Serina, Biagi, Mark, Lagnf, Abdalhamid M, Pullinger, Benjamin M, Cosimi, Reese, Kang-Birken, S Lena, Kunz Coyne, Ashlan J, Gore, Tristan, Agee, Jazmin, Veve, Michael P, Alosaimy, Sara, Rybak, Michael J, Al Musawa, Mohammed, Feehan Curley, Amy K, Judd, Chloe, Herbin, Shelbye R, Hobbs, Athena L V, Perkins, Nicholson B   +25 more
core  

Long-term trends in ceftolozane-tazobactam susceptibility among gram-negative pathogens in the United States: a nine-year SMART analysis (2016-2024). [PDF]

JAC Antimicrob Resist
Wise MG, Bauer KA, Esterly JS, Siddiqui F, Young K, Motyl MR, Sahm DF.   +6 more
europepmc   +1 more source

Difficult-to-treat resistance, not carbapenem non-susceptibility, is associated with 30-day mortality in respiratory gram-negative bacilli: a 12-year surveillance cohort. [PDF]

Front Cell Infect Microbiol
Shabi Y, Alwadei N, Alshahrani M, Somily AM, Binkhamis K, Asiri E, Mohamed S, Bawazeer AOS, Al Oudhah SM, Alqahtani RA, Alhamlan R, Salem E, Al Ghamdi B, Habtar G, Alqahtani A, Asiri F, Jali M, Almahdi H, Alahmari H.   +18 more
europepmc   +1 more source

Occurrence of β-lactamases among Enterobacterales isolates from 22 US hospitals in a 10-year period: report from the International Network for Optimal Resistance Monitoring (INFORM) programme. [PDF]

JAC Antimicrob Resist
Castanheira M, Doyle TB, Deshpande LM, Sader HS.   +3 more
europepmc   +1 more source

Beyond Colonization: Dynamic Risk Stratification and Clinical Decision-Making for MDR Gram-Negative Infections in Critically Ill Patients. [PDF]

Biomedicines
Gullì SP, Morena R, Serapide F, Russo A.   +3 more
europepmc   +1 more source

Prevalence and β-Lactam Resistance of Enterobacterales Isolated from Urinary Samples in a Regional Hospital in Poland: Special Emphasis on Elderly Population. [PDF]

Pathogens
Dudzik Ł, Migdał P, Misiąg P, Krzyżek P, Dworniczek E.   +4 more
europepmc   +1 more source